[Analysis of multimodal treatment outcome in renal cell carcinoma patients with bone metastasis].
We retrospectively reviewed the treatment outcome of 12 renal cell carcinoma (RCC) patients with bone metastasis who had undergone targeted therapy along with a regimen of multimodal treatment. We performed metastatectomy following nephrectomy on patients with resectable foci. Patients with unresectable bone metastasis underwent radiation therapy. With the exception of two patients, zoledronic acid was also administered. As a result, the overall survival rates of 83.3% at 1 year and 72.9% at 2 years in our study compared favorably with reported cases. Patients with complete resection of solitary bone metastasis with or without extrabone lesions had favorable outcomes. As differences in the response of the targeted therapy can be observed between bone and extrabone metastases, control of bone metastasis may be a key factor for the prognosis of metastatic RCC patients.